...one in fifty scientists
admitted they had
fabricated, falsified or
“doctored” a research
study...
It makes more sense when you understand that the drug companies with many millions or billions at stake are often funding the researchers or funding the universities for which the researchers work. And, of course, if the researchers’ studies produce the “right” results, they are more likely to continue to receive funding. Researchers who don’t get enough grant money from big pharmaceutical companies are likely to lose their university jobs. For some researchers, that can be reason enough to play along.
Playing along can mean a number of things. At its worst, playing along can result in complete fabrication or manipulation of the data and results.
It wasn’t long ago that Hwang Woo-Suk, South Korea’s once highly esteemed researcher, claimed a major breakthrough in

stem cell research and his results were also published in a prestigious, peer-reviewed publication. It was later found that he fabricated the data, for which he publicly apologized. While his fraud made headlines around the world, the crime might not be as rare as you think.
In 2008, one in fifty scientists admitted they had fabricated, falsified or “doctored” a research study; that number is generally
regarded as low since these researchers have an interest in keeping their frauds a secret. When these same scientists were asked if they knew a colleague who had fabricated the data or results, about one in seven said they knew someone who had done just that.
Questionable research practices fall below outright falsification of data and were found to be even more prevalent. When scientists were asked, about one in three admitting to having used questionable research practices; again, the number skyrocketed when asked if they knew a colleague who had. About seven out of every ten scientists said they knew a colleague who had used questionable research practices.
Questionable research includes practices like “changing the design, methodology or results of a study in response to pressures

from a funding source” or cherry-picking the results for publication. To the FDA, the latter is even acceptable.
In fact, by FDA rules, pharmaceutical companies can conduct as many clinical trials as they want, and send only the favorable results to the FDA for review. To help you read between the lines, this means drug companies can bury the negative results of clinical drug trials so that you and your doctor

never know about them.
Eli Lilly was accused of hiding the risk of suicide and suicidal tendencies with their drug Prozac, a drug now accepted to increase suicidal risk. A Harvard psychiatrist alleged that during the clinical trials those with suicidal tendencies were asked to leave the study, so their results were not counted. The Harvard psychiatrist was able to produce Eli Lilly internal documents to support the accusation.
Internal documents also surfaced to support the accusation that Eli Lilly knowingly hid the risks of their drug Zyprexa. A former FDA official even testified in court that the drug giant hid the risks for the purpose of insuring profits.